CONTESSA 2 - Clinical trial • Breast Cancer Foundation NZ

Donate to save lives this Breast Cancer Awareness Month.

CONTESSA 2

Advanced Breast Cancer clinical trials for ER+

Recruiting
Updated: July 6, 2020

This study will investigate the use of tesetaxel in patients with taxane-naïve, HER2-, HR+ locally advanced or metastatic breast cancer.

This study will investigate the use of tesetaxel in patients with taxane-naïve, HER2-, HR+ locally advanced or metastatic breast cancer.

Who is it for?

You may be eligible for this study if you meet the below criteria:

  • Female or male patients at least 18 years of age.
  • Histologically or cytologically confirmed breast cancer.
  • HER2- disease based on local testing: American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines should be utilized for assessing HER2 status.
  • HR+ (ER and/or PgR) disease based on local testing: ASCO/CAP guidelines should be utilized for assessing HR status.
  • Measurable disease per RECIST 1.1, including bone-only disease with measurable lytic component.
  • Patients with bone-only metastatic cancer must have a measurable lytic or mixed lytic-blastic lesion that can be accurately assessed by computerized tomography (CT) or magnetic resonance imaging (MRI). Patients with bone-only disease without a measurable lytic component (ie, blastic-only metastasis) are not eligible.
  • Known metastases to the CNS are permitted but not required. The following criteria apply: Patients must be neurologically stable and either off corticosteroids or currently treated with a maximum daily dose of 4 mg of dexamethasone (or equivalent), with no increase in corticosteroid dose within seven days prior to enrollment (defined as the time of Sponsor approval of treatment dose); patients with a history of CNS metastases but with no current evidence of CNS lesions following local therapy are eligible Patients may have CNS metastases that are stable or progressing radiologically; patients with current evidence of leptomeningeal disease are not eligible; patients may have untreated brain metastases or previously treated brain metastases, as long as no immediate local CNS-directed therapy is indicated; any prior whole brain radiation therapy must have been completed > 14 days prior to the date of Enrollment; prior stereotactic brain radiosurgery is permitted; CNS surgical resection must have been completed > 28 days prior to the date of Enrollment; patient must have complete recovery from surgery.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  • Prior endocrine therapy with or without a CDK 4/6 inhibitor unless endocrine therapy is not indicated (ie, short relapse-free interval while on adjuvant endocrine therapy [endocrine resistance]; rapidly progressing disease/visceral crisis; or endocrine intolerance). Any targeted therapies approved for HER2 negative, HR positive LA/MBC, including everolimus, are permitted as prior therapy. There is no limit to the number of prior endocrine therapies.
  • Documented (including de novo): (a) locally advanced breast cancer that is not considered curable by surgery and/or radiation; or (b) metastatic breast cancer.
  • Adequate hematologic, hepatic and renal function, as evidenced by: Absolute neutrophil count (ANC) = 1,500/µL without colony-stimulating factor support; platelet count = 100,000/µL; haemoglobin = 10 g/dL without need for hematopoietic growth factor or transfusion support; total bilirubin < 1.5 × upper limit of normal (ULN) - does not apply to patients with Gilbert's syndrome; alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present then < 5 × ULN; aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present then < 5 × ULN; alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present then < 5 ×ULN; calculated creatinine clearance = 50 mL/min (by Cockcroft-Gault formula or local standard); serum albumin = 3.0 g/dL; prothrombin time (PT) < 1.5 × ULN or international normalized ratio (INR) < 1.3 and partial thromboplastin time (PTT) < 1.5 × ULN, unless the patient is on a therapeutic anticoagulant.
  • Complete recovery to baseline or Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 from adverse effects of prior surgery, radiotherapy, endocrine therapy, and other therapy, as applicable, with the exception of Grade 2 alopecia from prior chemotherapy.
  • Ability to swallow an oral solid-dosage form of medication.
  • A negative serum pregnancy test within 7 days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for = one year or who have a history of hysterectomy or surgical sterilization).
  • Women of childbearing potential must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 70 days after the last dose of Study treatment. Acceptable methods include: copper intrauterine device or double barrier methods, including male/female condoms with spermicide and use of contraceptive sponge, cervical cap, or diaphragm.
  • Male patients must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 130 days after the last dose of Study treatment. Acceptable methods include: male/female condoms with spermicide, or vasectomy with medical confirmation of surgical success.
  • Written informed consent and authorization to use and disclose health information.
  • Ability to comprehend and comply with the requirements of the Study.

Study details

Participants will receive tesetaxel at 27 mg/m2 orally once every 21 days on the first day of each 21-day cycle plus capecitabine at 825 mg/m2 orally twice daily (for a total daily dose of 1,650 mg/m2) for 14 days of each 21-day cycle. Patients in the dense pharmacokinetics (PK) cohort will also receive a single dose of capecitabine monotherapy prior to starting the combination regimen. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in locally advanced/metastatic breast cancer. The primary endpoint is objective response rate as assessed by an IRC. The secondary efficacy endpoints are duration of response as assessed by the independent radiologic review committee, progression-free survival as assessed by the independent r adiologic review committee, disease control rate as assessed by the independent radiologic review committee and overall survival. CONTESSA 2 will also investigate the pharmacokinetics of tesetaxel.

For full trial information

Australia

Border Medical Oncology, Albury

Contact:

Stew Kroll

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.